

## AMENDMENT TO LICENSE AND TECHNOLOGY TRANSFER AGREEMENT

This amendment to the License and Technology Transfer Agreement (this "**Amendment**") is dated July 11, 2017 (the "**Amendment Effective Date**") by and between Bristol-Myers Squibb Company ("**BMS**") and the Medicines Patent Pool Foundation ("**MPP**"). BMS and MPP are each a "**Party**" hereto, and together, the "**Parties**."

### RECITALS

WHEREAS, BMS and MPP entered into a License and Technology Transfer Agreement dated 11 December 2013 as previously amended on 15 February 2016 (together, the "**Agreement**") to promote access to formulations of the antiretroviral drug atazanavir in a number of low- and middle-income countries;

WHEREAS, the Agreement contains a Form Sublicense Agreement attached as Schedule G, and

WHEREAS, the Parties wish to amend the Territory of both the Agreement and the Form Sublicense Agreement to include additional countries (collectively with the original territory, the "**Expanded Territory**").

All capitalized terms not otherwise defined herein shall have the meanings assigned to them in the Agreement.

NOW THEREFORE, based on the foregoing premises, the Parties hereby agree as follows:

1. Schedule D of the Agreement (Territory) is deleted in its entirety and replaced with Schedule D to this Amendment, representing the Expanded Territory.
2. Schedule D relating to Schedule G of the Agreement (Form Sublicense Agreement) is deleted in its entirety and replaced with Schedule D to this Amendment, representing the Expanded Territory.
3. Schedule B of the Agreement (Licensed Patent Rights) is deleted in its entirety and replaced with Schedule B to this Amendment.
4. Schedule B relating to Schedule G of the Agreement (Licensed Patent Rights) is deleted in its entirety and replaced with Schedule B to this Amendment.
5. Schedule C of the Agreement (Non-Territory Patent Rights) is deleted in its entirety and replaced with Schedule C to this Amendment.
6. Schedule C relating to Schedule G of the Agreement (Non-Territory Patent Rights) is deleted in its entirety and replaced with Schedule C to this Amendment.

Except as expressly set forth herein, the Agreement shall continue in full force and effect, and as amended or modified, the Agreement is hereby ratified, confirmed and approved. Notwithstanding the foregoing, in the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall control. No provision of this Amendment may be modified or amended except expressly in a writing signed by both parties nor shall any terms be modified or amended except expressly in a writing signed by both parties nor shall any terms be waived except expressly in a writing signed by the party charged therewith. This Amendment shall be governed in accordance with the laws of England. This Amendment may be executed in counterparts, including by facsimile or other electronic means, each of which will constitute an original, and both of which, when taken together, will constitute one and the same instrument.

[signature page follows]

IN WITNESS WHEREOF, the Parties have executed this Amendment to License and Technology Transfer Agreement by their duly authorized representatives as of the Amendment Effective Date.


**BRISTOL-MYERS SQUIBB COMPANY**

By: 

Name: Amadou Diarra

Title: Head, Global Policy, Advocacy & Gov't Affairs

**MEDICINES PATENT POOL FOUNDATION**

By: 

Name: Greg Perry

Title: Executive Director



Medicines Patent Pool  
Rue de Varembe 7  
1202 Geneva  
Switzerland

### Schedule B Licensed Patent Rights

The list below is accurate to the best of BMS knowledge as of the Effective Date of this Amendment. BMS has no obligation to update this list of the Licensed Patent Rights. It remains the responsibility of MPP and the Sublicensees to check for any changes in status.

#### Title: A PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS

Country	Filing Number	Filing	Grant Number	Grant Date
India	02933/DELNP/09	01 May 2009		
India	06425/DELNP/2006	03 May 2005		
South Africa	2006/9084	03 May 2005	2006/9084	27 August 2008

#### Title: TABLETED COMPOSITIONS CONTAINING ATAZANAVIR-HUB11023

Country	Filing Number	Filing	Grant Number	Grant Date
India	8328/DELNP/2009	20 June 2008		

#### Title: A PROCESS FOR THE PREPARATION OF ALPHA' CHLOROKETONES

Country	Filing Number	Filing	Grant Number	Grant
India	145/MUMNP/2003	20 Jul 2001	210496	05 Oct 2007

#### Title: STEREOSELECTIVE REDUCTION OF SUBSTITUTED OXO-BUTANES

Country	Filing Number	Filing	Grant Number	Grant Date
India	93/MUMNP/2003	20 Jul 2001	206217	19 Apr 2007

#### Title: BISULFATE SALT OF HIV PROTEASE INHIBITOR

Country	Filing Number	Filing	Grant Number	Grant Date
Ecuador	SP992834	19 Jan 1999		
Georgia	AP1998004009	22 Dec 1998	P3026	25 July 2003
Egypt	56/99	17 Jan 1999	23936	14 Jan 2008
Indonesia	W20001397	22 Dec 1998	ID0009860	10 Feb 2003
Malaysia	PI9900020	05 Jan 1999	MY-114838	31 Jan 2003
Pakistan	12/99	07 Jan 1999	136678	07 May 2001
Philippines	1-1998-03387	23 Dec 1998	1-1998-03387	14 Jul 2004
South Africa	990056	05 Jan 1999	990056	27 Sep 2000
Ukraine	2000084931/A	22 Dec 1998	59432	15 Sep 2003

#### Title: ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT

Country	Filing Number	Filing	Grant Number	Grant Sate
India	9097/CHENP/12	07 April 2011		

**Schedule C****Non-Territory Patent Rights**

The list below is accurate to the best of BMS knowledge as of the Effective Date. BMS has no obligation to update this list of the Non-Territory Patent Rights. It remains the responsibility of MPP and the Sublicensees to check for any changes in status.

**Title: PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Argentina	P150100592	27 Feb 2015		
Argentina	P050101776	03 May 2005		
Australia	2010201538	16 Apr 2010		
Australia	2005240622	03 May 2005	2005240622	27 May 2010
Austria	05744537.1	03 May 2005	1755596	12 Aug 2015
Belgium	05744537.1	03 May 2005	1755596	12 Aug 2015
Brazil	PI0509595.6	03 May 2005		
Bulgaria	05744537.1	03 May 2005	1755596	12 Aug 2015
Canada	2565629	03 May 2005	2565629	31 Jul 2012
Chile	1057/05	04 May 2005	50361	09 Sep 2014
Chile	3144/11	13 Dec 2011		
China	200910145402.X	18 May 2009	200910145402.X	14 Dec 2011
China	200580022550.2	03 May 2005	200580022550.2	30 Mar 2011
Croatia	05744537.1	03 May 2005	1755596	12 Aug 2015
Cyprus (Republic)	05744537.1	03 May 2005	1755596	12 Aug 2015
Czech Republic	05744537.1	03 May 2005	1755596	12 Aug 2015
Denmark	05744537.1	03 May 2005	1755596	12 Aug 2015
Estonia	05744537.1	03 May 2005	1755596	12 Aug 2015
European Procedure (Patents)	05744537.1	03 May 2005	1755596	12 Aug 2015
European Procedure (Patents)	15180557.9	11 Aug 2015		
Finland	05744537.1	03 May 2005	1755596	12 Aug 2015
France	05744537.1	03 May 2005	1755596	12 Aug 2015
Germany	05744537.1	03 May 2005	1755596	12 Aug 2015
Greece	05744537.1	03 May 2005	1755596	12 Aug 2015
Hong Kong	07103668.8	10 Apr 2007		
Hungary	05744537.1	03 May 2005	1755596	12 Aug 2015
Iceland	05744537.1	03 May 2005	1755596	12 Aug 2015
Ireland	05744537.1	03 May 2005	1755596	12 Aug 2015
Israel	178965	03 May 2005	178965	01 Sep 2011
Italy	05744537.1	03 May 2005	1755596	12 Aug 2015
Japan	2007-511502	03 May 2005	5086069	14 Sep 2012
Latvia	05744537.1	03 May 2005	1755596	12 Aug 2015
Lithuania	05744537.1	03 May 2005	1755596	12 Aug 2015
Luxembourg	05744537.1	03 May 2005	1755596	12 Aug 2015
Macedonia (F.Y.R.)	05744537.1	03 May 2005	1755596	12 Aug 2015
Mexico	PA/A/06/012612	03 May 2005	274189	19 Feb 2010
Monaco	05744537.1	03 May 2005	1755596	12 Aug 2015
Montenegro	05744537.1	03 May 2005	1755596	12 Aug 2015
Netherlands	05744537.1	03 May 2005	500151614	12 Aug 2015

**Title: PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Norway	20065441	03 May 2005		
Poland	05744537.1	03 May 2005	1755596	12 Aug 2015
Portugal	05744537.1	03 May 2005	1755596	12 Aug 2015
Romania	05744537.1	03 May 2005	1755596	12 Aug 2015
Russian Federation	2006142768	03 May 2005	2385325	27 Mar 2010
Serbia (ex-Serbia & Montenegro)	05744537.1	03 May 2005	1755596	12 Aug 2015
Singapore	200607509.7	03 May 2005	127083	14 Jan 2011
Slovakia	05744537.1	03 May 2005	1755596	12 Aug 2015
Slovenia	05744537.1	03 May 2005	1755596	12 Aug 2015
South Korea / Republic of Korea	10-2006-7025370	03 May 2005	10-1153606	30 May 2012
Spain	05744537.1	03 May 2005	300185023	12 Aug 2015
Sweden	05744537.1	03 May 2005	1755596	12 Aug 2015
Switzerland	05744537.1	03 May 2005	1755596	12 Aug 2015
Taiwan	103111712	28 Mar 2014	I-518072	21 Jan 2016
Taiwan	94114255	03 May 2005	I445697	21 Jul 2014
Turkey	05744537.1	03 May 2005	1755596	12 Aug 2015
United Kingdom	05744537.1	03 May 2005	1755596	12 Aug 2015
United States Of America	12/360468	27 Jan 2009	7838678	23 Nov 2010
United States Of America	12/900588	08 Oct 2010	8513428	20 Aug 2013
United States Of America	11/119558	02 May 2005	7829720	09 Nov 2010
Venezuela	VN05/000854	04 May 2005		

**Title: TABLETED COMPOSITIONS CONTAINING ATAZANAVIR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Australia	2008268625	15 Mar 2016	2008268625	30 Sep 2016
Australia	2008268625	20 Jun 2008	2008268625	13 Mar 2014
Austria	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Belgium	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Bulgaria	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Croatia	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Cyprus (Republic)	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Czech Republic	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Denmark	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Estonia	08771562.9	20 Jun 2008	2170292	08 Jan 2014
European Procedure (Patents)	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Finland	08771562.9	20 Jun 2008	2170292	08 Jan 2014
France	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Germany	08771562.9	20 Jun 2008	602008029796.9	08 Jan 2014
Greece	08771562.9	20 Jun 2008	3083177	08 Jan 2014
Gulf Cooperation Council	11117	22 Jun 2008		

**Title: TABLETED COMPOSITIONS CONTAINING ATAZANAVIR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Hungary	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Iceland	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Ireland	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Italy	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Japan	2014-031942	21 Feb 2014	5869600	15 Jan 2016
Japan	2015-218828	06 Nov 2015	6154878	09 Jun 2017
Japan	2010-513431	20 Jun 2008		
Latvia	08771562.9	20 Jun 2008		
Lebanon	8336	13 Jun 2008	8336	23 Jul 2009
Lithuania	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Luxembourg	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Malta	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Mexico	MX/A/09/013504	20 Jun 2008	312207	12 Aug 2013
Monaco	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Netherlands	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Norway	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Poland	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Portugal	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Romania	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Slovakia	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Slovenia	08771562.9	20 Jun 2008	2170292	08 Jan 2014
South Korea / Republic of Korea	2009-7026607	20 Jun 2008	1686243	07 Dec 2016
Spain	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Sweden	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Switzerland	08771562.9	20 Jun 2008	2170292	08 Jan 2014
Thailand	0801003176	20 Jun 2008		
Turkey	08771562.9	20 Jun 2008	2170292	08 Jan 2014
United Kingdom	08771562.9	20 Jun 2008	2170292	08 Jan 2014
United States Of America	13/906651	31 May 2013		

**Title: TABLETED COMPOSITIONS CONTAINING ATAZANAVIR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Australia	2008268537	20 Jun 2008	2008268537	14 Feb 2013
Austria	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Belgium	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Bulgaria	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Croatia	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Cyprus (Republic)	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Czech Republic	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Denmark	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Estonia	08771569.4	20 Jun 2008	2178513	30 Mar 2011
European Procedure (Patents)	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Finland	08771569.4	20 Jun 2008	2178513	30 Mar 2011
France	08771569.4	20 Jun 2008	2178513	30 Mar 2011

**Title: TABLETED COMPOSITIONS CONTAINING ATAZANAVIR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Germany	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Greece	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Hungary	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Iceland	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Ireland	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Italy	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Latvia	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Lithuania	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Luxembourg	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Malta	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Mexico	MX/A/09/013461	20 Jun 2008	290355	22 Sep 2011
Monaco	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Netherlands	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Norway	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Poland	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Portugal	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Romania	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Slovakia	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Slovenia	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Spain	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Sweden	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Switzerland	08771569.4	20 Jun 2008	2178513	30 Mar 2011
Turkey	08771569.4	20 Jun 2008	2178513	30 Mar 2011
United Kingdom	08771569.4	20 Jun 2008	2178513	30 Mar 2011

**Title: A PROCESS FOR THE PREPARATION OF ALPHA' CHLOROKETONES**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Australia	2001/282944	20 Jul 2001	2001282944	01 Dec 2005
Austria	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Belgium	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Brazil	PI0112820.5	20 Jul 2001		
China	01814164.1	20 Jul 2001	ZL01814164.1	19 Jul 2006
Cyprus (Republic)	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Czech Republic	2003-419	20 Jul 2001	301422	14 Jan 2010
Denmark	01961698.6	20 Jul 2001	1309535	26 Mar 2008
European Procedure (Patents)	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Finland	01961698.6	20 Jul 2001	1309535	26 Mar 2008
France	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Germany	01961698.6	20 Jul 2001	60133395.0	26 Mar 2008
Greece	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Hong Kong	03104335.3	17 Jun 2003	1052001	04 Jul 2008
Hungary	P03023344	20 Jul 2001	229795	27 Aug 2014
Ireland	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Israel	153830	20 Jul 2001	153830	01 Dec 2012
Italy	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Japan	2002/519403	20 Jul 2001	4889909	22 Dec 2011



**Title: A PROCESS FOR THE PREPARATION OF ALPHA' CHLOROKETONES**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Luxembourg	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Mexico	PA/A/03/001314	20 Jul 2001	232127	11 Nov 2005
Monaco	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Netherlands	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Portugal	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Singapore	200300524-6	20 Jul 2001	94663	29 Oct 2004
South Korea / Republic of Korea	2003-7002215	20 Jul 2001	768961	09 Oct 2007
Spain	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Sweden	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Switzerland	01961698.6	20 Jul 2001	1309535	26 Mar 2008
Taiwan	90119584	10 Aug 2001	NI-233925	11 Jun 2005
Turkey	01961698.6	20 Jul 2001	1309535	26 Mar 2008
United Kingdom	01961698.6	20 Jul 2001	1309535	26 Mar 2008
United States Of America	09/908516	18 Jul 2001	6399793	04 Jun 2002

**Title: STEREOSELECTIVE REDUCTION OF SUBSTITUTED OXO-BUTANES**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Australia	2001/280698	20 Jul 2001	2001280698	09 Dec 2005
Brazil	PI0113236.9	20 Jul 2001	PI0113236.9	22 Apr 2014
China	01814196.X	20 Jul 2001	01814196.X	27 Apr 2007
Czech Republic	PV2003-758	20 Jul 2001	303884	02 May 2013
European Procedure (Patents)	01959109.8	20 Jul 2001	1309714	13 May 2009
France	01959109.8	20 Jul 2001	1309714	13 May 2009
Germany	01959109.8	20 Jul 2001	1309714	13 May 2009
Hungary	P0300873	20 Jul 2001	229338	08 Oct 2013
Italy	01959109.8	20 Jul 2001	1309714	13 May 2009
Japan	2002-519654	20 Jul 2001	3843255	18 Aug 2006
Mexico	PA/A/03/001312	20 Jul 2001	245407	26 Apr 2007
Singapore	200300523-8	20 Jul 2001	94662	30 Nov 2006
Spain	01959109.8	20 Jul 2001	1309714	13 May 2009
Taiwan	90120123	16 Aug 2001	NI287579	01 Oct 2007
United Kingdom	01959109.8	20 Jul 2001	1309714	13 May 2009
United States Of America	10/661893	12 Sep 2003	7083973	01 Aug 2006

**Title: BMS-232632 HIV PROTEASE INHIBITOR - ATAZANAVIR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Australia	23859/97	14 Apr 1997	706183	23 Sep 1999
Austria	SZ29/2005	30 Jun 2005	SZ29/2005	24 Aug 2007
Belgium	2005C/028	30 Jun 2005	2005C/028	06 Feb 2007
Denmark	CA200500037	11 Jul 2005	CR200500037	23 Jun 2008
Finland	L20050019	14 Apr 1997	260	09 Oct 2009

**Title: BMS-232632 HIV PROTEASE INHIBITOR - ATAZANAVIR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
France	05C0030	05 Jul 2005	05C0030	27 Apr 2007
Germany	122005000003.5	01 Feb 2005	122005000003.5	16 Jul 2012
Greece	2005800019	27 Jul 2005	8000186	27 Apr 2006
Italy	43085	20 Jul 2005	892	20 Sep 2005
Japan	2004-70023	16 Mar 2004	3174347	23 Feb 2005
Japan	2004-70024	06 Mar 2004	3174347	23 Feb 2005
Luxembourg	91189	03 Aug 2005	91189	03 Oct 2005
Netherlands	300203	28 Jul 2005	300203	30 Aug 2005
Portugal	205	19 Jul 2005	205	04 Aug 2005
Romania	C/067	25 Jun 2007	C/067	30 Mar 2011
Slovenia	C200540011	03 Aug 2005	C200540011	30 Apr 2006
Spain	200500033	17 Oct 2008	200500033	17 Oct 2008
Sweden	0590027-9	03 Aug 2005	0590027-9	10 Jan 2006
Switzerland	C00900210/01	09 Feb 2005	C00900210/01	30 Jun 2006
United Kingdom	SPC/GB05/036	21 Jul 2005	SPC/GB05/036	06 Feb 2006
United States Of America	08/831630	14 Aug 2003	5849911	09 Mar 2007

**Title: A PROCESS FOR PREPARING (2R,3S)1,2-EPOXY-3- (PROTECTED) AMINO-4-SUBSTITUTED BUTANE AND INTERMEDIATES THEREOF**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
European Procedure (Patents)	06750625.3	19 Apr 2006	1893765	30 Nov 2011
France	06750625.3	19 Apr 2006	1893765	30 Nov 2011
Germany	06750625.3	19 Apr 2006	1893765	30 Nov 2011
Italy	06750625.3	19 Apr 2006	1893765	30 Nov 2011
Spain	06750625.3	19 Apr 2006	1893765	30 Nov 2011
United Kingdom	06750625.3	19 Apr 2006	1893765	30 Nov 2011
United States Of America	12/506596	21 Jul 2009	8119389	21 Feb 2012
United States Of America	11/365275	01 Mar 2006	7582468	01 Sep 2009

**Title: BISULFATE SALT OF HIV PROTEASE INHIBITOR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Argentina	P990100179	18 Jan 1999	AR014417B1	13 Apr 2005
Australia	20101/99	22 Dec 1998	735875	01 Nov 2001
Austria	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Belgium	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Bulgaria	104618	22 Dec 1998	64774	29 Dec 2005
Bulgaria	07/038	13 Jun 2007	07/038	16 Aug 2008
Canada	2317736	22 Dec 1998	2317736	02 Nov 2004
Chile	1999-034	08 Jan 1999	41834	03 Jun 2003
China	98812741.5	22 Dec 1998	ZL98812741.5	30 Jul 2003
Colombia	99002578	19 Jan 1999		
Cyprus (Republic)	98964878.7	22 Dec 1998	CY 1100263	12 Jun 2002

**Title: BISULFATE SALT OF HIV PROTEASE INHIBITOR**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
Czech Republic	PV20002564	22 Dec 1998	293507	15 Mar 2004
Denmark	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Estonia	0425/00PC	22 Dec 1998	04434	15 Feb 2004
European Procedure (Patents)	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Finland	98964878.7	22 Dec 1998	1056722	12 Jun 2002
France	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Germany	98964878.7	22 Dec 1998	69806067.9	12 Jun 2002
Greece	98964878.7	22 Dec 1998	3040802	12 Jun 2002
Hong Kong	01103011.8	26 Apr 2001	1033667	24 Jan 2003
Hong Kong	01104126.8	15 Jun 2001	1033458	07 May 2004
Hungary	P0101389	22 Dec 1998	227196	05 Jan 2011
Ireland	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Israel	137384	22 Dec 1998	137384	02 Nov 2006
Italy	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Japan	2000540121	22 Dec 1998	4860037	11 Nov 2011
Latvia	P0078	22 Dec 1998	12522	20 Oct 2000
Lithuania	2000-067	22 Dec 1998	4780	25 Apr 2001
Luxembourg	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Mexico	6747	22 Dec 1998	215127	08 Jul 2003
Monaco	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Netherlands	98964878.7	22 Dec 1998	NL1056722	12 Jun 2002
New Zealand	504417	22 Dec 1998	504417	10 Jan 2002
Norway	20003692	22 Dec 1998	315605	29 Sep 2003
Peru	0047/99	20 Jan 1999	002380	29 Apr 2002
Poland	P342019	22 Dec 1998	190744	19 Aug 2005
Portugal	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Romania	200000717	22 Dec 1998	118869	30 Dec 2003
Russian Federation	2000119792	22 Dec 1998	2186070	27 Jul 2002
Singapore	200002607-0	22 Dec 1998	73159	21 Jan 2003
Slovakia	PV1062-2000	22 Dec 1998	283975	19 Apr 2004
Spain	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Sweden	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Switzerland	98964878.7	22 Dec 1998	1056722	12 Jun 2002
Taiwan	88100623	15 Jan 1999	1177855	09 Sep 2003
Thailand	048191	14 Jan 1999	20875	10 Nov 2006
Turkey	00/1876	22 Dec 1998	TR200001876B	21 Jun 2001
United Kingdom	98964878.7	22 Dec 1998	1056722	12 Jun 2002
United States Of America	09/217538	21 Dec 1998	6087383	11 Jul 2000
Venezuela	1999-000084	20 Jan 1999		

**Title: ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT**

<b>Country</b>	<b>Filing Number</b>	<b>Filing</b>	<b>Grant Number</b>	<b>Grant Date</b>
China	201180028213.X	07 Apr 2011		
Japan	2013-503940	07 Apr 2011		

**SCHEDULE D**  
**TERRITORY**

Afghanistan	Madagascar*
Algeria**	Malawi*
Angola*	Maldives
Antigua and Barbuda	Mali*
Armenia*	Marshall Island
Azerbaijan	Mauritania*
Bangladesh	Mauritius*
Belarus*	Malaysia**
Belize	Micronesia, Federated States
Benin*	Moldova
Bhutan	Mongolia
Bolivia	Morocco**
Botswana*	Mozambique*
Burkina Faso*	Myanmar
Burundi*	Namibia*
Cambodia*	Nauru
Cameroon*	Nepal
Cape Verde*	Nicaragua*
Central African Republic*	Niger*
Chad*	Nigeria*
Comoros*	Niue**
Congo, Dem. Rep. *	Pakistan
Congo, Rep. *	Palau
Cook Islands**	Panama
Costa Rica	Papua New Guinea
Côte d'Ivoire*	Philippines**
Cuba	Rwanda*
Djibouti*	Samoa
Dominica*	São Tomé and Príncipe*
Dominican Republic	Senegal*
Ecuador	Seychelles*
Egypt**	Sierra Leone*
El Salvador	Solomon Islands
Equatorial Guinea**	Somalia*
Eritrea*	South Africa*
Ethiopia*	South Sudan
Fiji	Sri Lanka
Gabon*	St. Kitts and Nevis
Gambia, The*	St. Lucia
Georgia	St. Vincent and the Grenadines
Ghana*	Sudan*
Grenada	Suriname
Guatemala	Swaziland*
Guinea*	Syrian Arab Republic
Guinea-Bissau*	Tajikistan
	Tanzania*

Guyana  
Haiti  
Honduras  
India\*  
Indonesia\*\*  
Iraq  
Jamaica  
Kazakhstan  
Kenya\*  
Kiribati  
Korea, Dem. Rep.  
Kyrgyz Republic  
Lao PDR  
Lesotho\*  
Liberia\*  
Libya

Timor-Leste  
Togo\*  
Tonga  
Tunisia\*\*  
Turkmenistan  
Tuvalu  
Uganda\*  
Ukraine\*\*  
Uzbekistan  
Vanuatu  
Vietnam\*\*  
West Bank and Gaza  
Yemen, Rep.  
Zambia\*  
Zimbabwe\*

\*Country previously included in one or more BMS agreements in relation to Licensed Patent Rights. According to Section 3.1(a) no royalties will be due by the Sublicensees for sales in such country.

\*\* Added as of the Amendment Effective Date.